Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 879523, 11 pages
http://dx.doi.org/10.1155/2008/879523
Review Article

Peroxisome Proliferator-Activated Receptors in Diabetic Nephropathy

1Department of Medicine, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan
2Division of Endocrinology and Metabolism, Department of Internal Medicine, Kanazawa Medical University, Ishikawa 920-0293, Japan

Received 30 August 2008; Accepted 8 December 2008

Academic Editor: Nigel Brunskill

Copyright © 2008 Shinji Kume et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. H. Mokdad, E. S. Ford, B. A. Bowman et al., “Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001,” The Journal of the American Medical Association, vol. 289, no. 1, pp. 76–79, 2003. View at Publisher · View at Google Scholar
  2. A. F. Amos, D. J. McCarty, and P. Zimmet, “The rising global burden of diabetes and its complications: estimates and projections to the year 2010,” Diabetic Medicine, vol. 14, supplement 5, pp. S7–S85, 1997. View at Google Scholar
  3. A. N. Lasaridis and P. A. Sarafidis, “Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials?” American Journal of Hypertension, vol. 16, no. 8, pp. 689–697, 2003. View at Publisher · View at Google Scholar
  4. M. E. Molitch, R. A. DeFronzo, M. J. Franz et al., “Nephropathy in diabetes,” Diabetes Care, vol. 27, supplement 1, pp. S79–S83, 2004. View at Google Scholar
  5. J. C. Corton, S. P. Anderson, and A. Stauber, “Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators,” Annual Review of Pharmacology and Toxicology, vol. 40, pp. 491–518, 2000. View at Publisher · View at Google Scholar
  6. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar
  7. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, “Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors,” Cell, vol. 68, no. 5, pp. 879–887, 1992. View at Publisher · View at Google Scholar
  8. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar
  9. L. Fajas, M. B. Debril, and J. Auwerx, “Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis,” Journal of Molecular Endocrinology, vol. 27, no. 1, pp. 1–9, 2001. View at Publisher · View at Google Scholar
  10. Y. Guan and M. D. Breyer, “Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease,” Kidney International, vol. 60, no. 1, pp. 14–30, 2001. View at Publisher · View at Google Scholar
  11. T. M. Willson, M. H. Lambert, and S. A. Kliewer, “Peroxisome proliferator-activated receptor γ and metabolic disease,” Annual Review of Biochemistry, vol. 70, pp. 341–367, 2001. View at Publisher · View at Google Scholar
  12. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.-C. Fruchart, “Mechanism of action of fibrates on lipid and lipoprotein metabolism,” Circulation, vol. 98, no. 19, pp. 2088–2093, 1998. View at Google Scholar
  13. G. D. Wu, “A nuclear receptor to prevent colon cancer,” The New England Journal of Medicine, vol. 342, no. 9, pp. 651–653, 2000. View at Publisher · View at Google Scholar
  14. C.-H. Lee, P. Olson, A. Hevener et al., “PPARd regulates glucose metabolism and insulin sensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 9, pp. 3444–3449, 2006. View at Publisher · View at Google Scholar
  15. J. Auwerx, “PPARγ, the ultimate thrifty gene,” Diabetologia, vol. 42, no. 9, pp. 1033–1049, 1999. View at Publisher · View at Google Scholar
  16. A. B. Jones, “Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond,” Medicinal Research Reviews, vol. 21, no. 6, pp. 540–552, 2001. View at Publisher · View at Google Scholar
  17. L. Fajas, J.-C. Fruchart, and J. Auwerx, “PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter,” FEBS Letters, vol. 438, no. 1-2, pp. 55–60, 1998. View at Publisher · View at Google Scholar
  18. E. D. Rosen and B. M. Spiegelman, “PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth,” Journal of Biological Chemistry, vol. 276, no. 41, pp. 37731–37734, 2001. View at Publisher · View at Google Scholar
  19. L. Fajas, D. Auboeuf, E. Raspé et al., “The organization, promoter analysis, and expression of the human PPAR? gene,” Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997. View at Publisher · View at Google Scholar
  20. P. Escher and W. Wahli, “Peroxisome proliferator-activated receptors: insight into multiple cellular functions,” Mutation Research, vol. 448, no. 2, pp. 121–138, 2000. View at Publisher · View at Google Scholar
  21. C. E. Juge-Aubry, E. Hammar, C. Siegrist-Kaiser et al., “Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor a by phosphorylation of a ligand-independent trans-activating domain,” Journal of Biological Chemistry, vol. 274, no. 15, pp. 10505–10510, 1999. View at Publisher · View at Google Scholar
  22. D. Shao, S. M. Rangwala, S. T. Bailey, S. L. Krakow, M. J. Reginato, and M. A. Lazar, “Interdomain communication regulating ligand binding by PPAR-γ,” Nature, vol. 396, no. 6709, pp. 377–380, 1998. View at Publisher · View at Google Scholar
  23. S. A. Kliewer, H. E. Xu, M. H. Lambert, and T. M. Willson, “Peroxisome proliferator-activated receptors: from genes to physiology,” Recent Progress in Hormone Research, vol. 56, pp. 239–263, 2001. View at Publisher · View at Google Scholar
  24. D. Moras and H. Gronemeyer, “The nuclear receptor ligand-binding domain: structure and function,” Current Opinion in Cell Biology, vol. 10, no. 3, pp. 384–391, 1998. View at Publisher · View at Google Scholar
  25. P. Ellinghaus, C. Wolfrum, G. Assmann, F. Spener, and U. Seedorf, “Phytanic acid activates the peroxisome proliferator-activated receptor α (PPARα) in sterol carrier protein 2-/sterol carrier protein x-deficient mice,” Journal of Biological Chemistry, vol. 274, no. 5, pp. 2766–2772, 1999. View at Publisher · View at Google Scholar
  26. S. A. Kliewer, S. S. Sundseth, S. A. Jones et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors a and ?,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318–4323, 1997. View at Publisher · View at Google Scholar
  27. Q. Lin, S. E. Ruuska, N. S. Shaw, D. Dong, and N. Noy, “Ligand selectivity of the peroxisome proliferator-activated receptor α,” Biochemistry, vol. 38, no. 1, pp. 185–190, 1999. View at Publisher · View at Google Scholar
  28. S. Y. Moya-Camarena, J. P. Vanden Heuvel, S. G. Blanchard, L. A. Leesnitzer, and M. A. Belury, “Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARα,” Journal of Lipid Research, vol. 40, no. 8, pp. 1426–1433, 1999. View at Google Scholar
  29. L. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, “Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ,” Cell, vol. 93, no. 2, pp. 229–240, 1998. View at Publisher · View at Google Scholar
  30. P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998. View at Publisher · View at Google Scholar
  31. K. G. Lambe and J. D. Tugwood, “A human peroxisome-proliferator-activated receptor-γ is activated by inducers of adipogenesis, including thiazalidinedione drugs,” European Journal of Biochemistry, vol. 239, no. 1, pp. 1–7, 1996. View at Publisher · View at Google Scholar
  32. B. B. Lowell, “PPARγ: an essential regulator of adipogenesis and modulator of fat cell function,” Cell, vol. 99, no. 3, pp. 239–242, 1999. View at Publisher · View at Google Scholar
  33. E. D. Rosen, P. Sarraf, A. E. Troy et al., “PPAR? is required for the differentiation of adipose tissue in vivo and in vitro,” Molecular Cell, vol. 4, no. 4, pp. 611–617, 1999. View at Publisher · View at Google Scholar
  34. B. M. Spiegelman, E. Hu, J. B. Kim, and R. Brun, “PPARγ and the control of adipogenesis,” Biochimie, vol. 79, no. 2-3, pp. 111–112, 1997. View at Publisher · View at Google Scholar
  35. Z. Wu, E. D. Rosen, R. Brun et al., “Cross-regulation of C/EBPa and PPAR? controls the transcriptional pathway of adipogenesis and insulin sensitivity,” Molecular Cell, vol. 3, no. 2, pp. 151–158, 1999. View at Publisher · View at Google Scholar
  36. S. C. Benson, H. A. Pershadsingh, C. I. Ho et al., “Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR?-modulating activity,” Hypertension, vol. 43, no. 5, pp. 993–1002, 2004. View at Publisher · View at Google Scholar
  37. M. Schupp, J. Janke, R. Clasen, T. Unger, and U. Kintscher, “Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity,” Circulation, vol. 109, no. 17, pp. 2054–2057, 2004. View at Publisher · View at Google Scholar
  38. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Publisher · View at Google Scholar
  39. J.-L. Su, C. J. Simmons, B. Wisely, B. Ellis, and D. A. Winegar, “Monitoring of PPAR alpha protein expression in human tissue by the use of PPAR alpha-specific MAbs,” Hybridoma, vol. 17, no. 1, pp. 47–53, 1998. View at Google Scholar
  40. D. Auboeuf, J. Rieusset, L. Fajas et al., “Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-a in humans: no alteration in adipose tissue of obese and NIDDM patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997. View at Publisher · View at Google Scholar
  41. Y. Guan, Y. Zhang, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans,” American Journal of Physiology, vol. 273, no. 6, pp. F1013–F1022, 1997. View at Google Scholar
  42. R. Mukherjee, L. Jow, G. E. Croston, and J. R. Paterniti Jr., “Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists,” Journal of Biological Chemistry, vol. 272, no. 12, pp. 8071–8076, 1997. View at Publisher · View at Google Scholar
  43. S. A. Kliewer, B. M. Forman, B. Blumberg et al., “Differential expression and activation of a family of murine peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355–7359, 1994. View at Publisher · View at Google Scholar
  44. T. Yang, D. E. Michele, J. Park et al., “Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney,” American Journal of Physiology, vol. 277, no. 6, pp. F966–F973, 1999. View at Google Scholar
  45. T. Asano, M. Wakisaka, M. Yoshinari et al., “Peroxisome proliferator-activated receptor ?1 (PPAR?1) expresses in rat mesangial cells and PPAR? agonists modulate its differentiation,” Biochimica et Biophysica Acta, vol. 1497, no. 1, pp. 148–154, 2000. View at Publisher · View at Google Scholar
  46. Y. Iwashima, M. Eto, S. Horiuchi, and H. Sano, “Advanced glycation end product-induced peroxisome proliferator-activated receptor γ gene expression in the cultured mesangial cells,” Biochemical and Biophysical Research Communications, vol. 264, no. 2, pp. 441–448, 1999. View at Publisher · View at Google Scholar
  47. K. Sato, A. Sugawara, M. Kudo, A. Uruno, S. Ito, and K. Takeuchi, “Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney,” Hypertension Research, vol. 27, no. 6, pp. 417–425, 2004. View at Publisher · View at Google Scholar
  48. Y. Kamijo, K. Hora, N. Tanaka et al., “Identification of functions of peroxisome proliferator-activated receptor a in proximal tubules,” Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1691–1702, 2002. View at Publisher · View at Google Scholar
  49. D. M. Gorson, “Significant weight gain with rezulin therapy,” Archives of Internal Medicine, vol. 159, no. 1, p. 99, 1999. View at Publisher · View at Google Scholar
  50. T. Yoshimoto, M. Naruse, M. Nishikawa et al., “Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats,” American Journal of Physiology, vol. 272, no. 6, pp. E989–E996, 1997. View at Google Scholar
  51. S. Yoshioka, H. Nishino, T. Shiraki et al., “Antihypertensive effects of CS-045 treatment in obese Zucker rats,” Metabolism, vol. 42, no. 1, pp. 75–80, 1993. View at Publisher · View at Google Scholar
  52. C. Baylis, E.-A. Atzpodien, G. Freshour, and K. Engels, “Peroxisome proliferator-activated receptor γ agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity,” Journal of Pharmacology and Experimental Therapeutics, vol. 307, no. 3, pp. 854–860, 2003. View at Publisher · View at Google Scholar
  53. R. E. Buckingham, K. A. Al-Barazanji, C. D. Toseland et al., “Peroxisome proliferator-activated receptor-? agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats,” Diabetes, vol. 47, no. 8, pp. 1326–1334, 1998. View at Publisher · View at Google Scholar
  54. M. Fujii, R. Takemura, M. Yamaguchi et al., “Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats,” Metabolism, vol. 46, no. 9, pp. 981–983, 1997. View at Publisher · View at Google Scholar
  55. K. Fujiwara, K. Hayashi, Y. Ozawa, H. Tokuyama, A. Nakamura, and T. Saruta, “Renal protective effect of troglitazone in Wistar fatty rats,” Metabolism, vol. 49, no. 10, pp. 1361–1364, 2000. View at Publisher · View at Google Scholar
  56. K. Isshiki, M. Haneda, D. Koya, S. Maeda, T. Sugimoto, and R. Kikkawa, “Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats,” Diabetes, vol. 49, no. 6, pp. 1022–1032, 2000. View at Publisher · View at Google Scholar
  57. O. Khan, S. Riazi, X. Hu, J. Song, J. B. Wade, and C. A. Ecelbarger, “Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone,” American Journal of Physiology, vol. 289, no. 2, pp. F442–F450, 2005. View at Publisher · View at Google Scholar
  58. S. B. Nicholas, Y. Kawano, S. Wakino, A. R. Collins, and W. A. Hsueh, “Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells,” Hypertension, vol. 37, no. 2, pp. 722–727, 2001. View at Google Scholar
  59. M. Tanimoto, Q. Fan, T. Gohda, T. Shike, Y. Makita, and Y. Tomino, “Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice,” Metabolism, vol. 53, no. 11, pp. 1473–1479, 2004. View at Publisher · View at Google Scholar
  60. H. Yamashita, Y. Nagai, T. Takamura, E. Nohara, and K. Kobayashi, “Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat,” Metabolism, vol. 51, no. 4, pp. 403–408, 2002. View at Publisher · View at Google Scholar
  61. D. Portilla, “Energy metabolism and cytotoxicity,” Seminars in Nephrology, vol. 23, no. 5, pp. 432–438, 2003. View at Publisher · View at Google Scholar
  62. F. Ouali, F. Djouadi, C. Merlet-Bénichou, and J. Bastin, “Dietary lipids regulate β-oxidation enzyme gene expression in the developing rat kidney,” American Journal of Physiology, vol. 275, no. 5, pp. F777–F784, 1998. View at Google Scholar
  63. C. W. Park, Y. Zhang, X. Zhang et al., “PPARa agonist fenofibrate improves diabetic nephropathy in db/db mic,” Kidney International, vol. 69, no. 9, pp. 1511–1517, 2006. View at Publisher · View at Google Scholar
  64. X. Zhao and L.-Y. Li, “PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats,” American Journal of Nephrology, vol. 28, no. 4, pp. 598–606, 2008. View at Publisher · View at Google Scholar
  65. A. M. Sironi, S. Vichi, A. Gastaldelli et al., “Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes,” Clinical Pharmacology and Therapeutics, vol. 62, no. 2, pp. 194–202, 1997. View at Publisher · View at Google Scholar
  66. E. Imano, T. Kanda, Y. Nakatani et al., “Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy,” Diabetes Care, vol. 21, no. 12, pp. 2135–2139, 1998. View at Publisher · View at Google Scholar
  67. T. Nakamura, C. Ushiyama, S. Suzuki et al., “Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria,” Diabetic Medicine, vol. 18, no. 4, pp. 308–313, 2001. View at Publisher · View at Google Scholar
  68. T. Nakamura, C. Ushiyama, N. Shimada, K. Hayashi, I. Ebihara, and H. Koide, “Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients,” Journal of Diabetes and its Complications, vol. 14, no. 5, pp. 250–254, 2000. View at Publisher · View at Google Scholar
  69. T. Nakamura, C. Ushiyama, S. Osada, M. Hara, N. Shimada, and H. Koide, “Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria,” Metabolism, vol. 50, no. 10, pp. 1193–1196, 2001. View at Publisher · View at Google Scholar
  70. K. Aljabri, S. E. Kozak, and D. M. Thompson, “Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial,” American Journal of Medicine, vol. 116, no. 4, pp. 230–235, 2004. View at Publisher · View at Google Scholar
  71. T. Yanagawa, A. Araki, K. Sasamoto, S. Shirabe, and T. Yamanouchi, “Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes,” Metabolism, vol. 53, no. 3, pp. 353–357, 2004. View at Publisher · View at Google Scholar
  72. M. Hanefeld, P. Brunetti, G. H. Schernthaner, D. R. Matthews, and B. H. Charbonnel, “One-year glycemic control with a suifonyurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes,” Diabetes Care, vol. 27, no. 1, pp. 141–147, 2004. View at Publisher · View at Google Scholar
  73. G. Schernthaner, D. R. Matthews, B. Charbonnel, M. Hanefeld, and P. Brunetti, “Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 12, pp. 6068–6076, 2004. View at Publisher · View at Google Scholar
  74. D. R. Matthews, B. H. Charbonnel, M. Hanefeld, P. Brunetti, and G. Schernthaner, “Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study,” Diabetes/Metabolism Research and Reviews, vol. 21, no. 2, pp. 167–174, 2005. View at Publisher · View at Google Scholar
  75. R. Agarwal, C. Saha, M. Battiwala et al., “A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy,” Kidney International, vol. 68, no. 1, pp. 285–292, 2005. View at Publisher · View at Google Scholar
  76. H. E. Lebovitz, J. F. Dole, R. Patwardhan, E. B. Rappaport, and M. I. Freed, “Rosiglitazone monotherapy is effective in patients with type 2 diabetes,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 1, pp. 280–288, 2001. View at Publisher · View at Google Scholar
  77. P. A. Sarafidis, A. N. Lasaridis, P. M. Nilsson et al., “The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension,” American Journal of Hypertension, vol. 18, no. 2, pp. 227–234, 2005. View at Publisher · View at Google Scholar
  78. F. Pistrosch, K. Herbrig, B. Kindel, J. Passauer, S. Fischer, and P. Gross, “Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients,” Diabetes, vol. 54, no. 7, pp. 2206–2211, 2005. View at Publisher · View at Google Scholar
  79. G. R. Dagenais, H. C. Gerstein, R. Holman et al., “Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial,” Diabetes Care, vol. 31, no. 5, pp. 1007–1014, 2008. View at Publisher · View at Google Scholar
  80. L. F. Fried, T. J. Orchard, and B. L. Kasiske, “Effect of lipid reduction on the progression of renal disease: a meta-analysis,” Kidney International, vol. 59, no. 1, pp. 260–269, 2001. View at Publisher · View at Google Scholar
  81. Y. M. Smolders, A. E. van Eeden, C. D. A. Stehouwer, R. N. M. Weijers, E. H. Slaats, and J. Silberbusch, “Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?” European Journal of Clinical Investigation, vol. 27, no. 12, pp. 997–1002, 1997. View at Google Scholar
  82. A. Keech, R. J. Simes, P. Barter et al., “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” The Lancet, vol. 366, no. 9500, pp. 1849–1861, 2005. View at Publisher · View at Google Scholar
  83. H. Shamoon, H. Duffy, N. Fleischer et al., “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993. View at Publisher · View at Google Scholar
  84. UK Prospective Diabetes Study (UKPDS) Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar
  85. V. A. Fonseca, T. R. Valiquett, S. M. Huang et al., “Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study,” The Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 9, pp. 3169–3176, 1998. View at Publisher · View at Google Scholar
  86. S. Kumar, A. J. M. Boulton, H. Beck-Nielsen et al., “Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients,” Diabetologia, vol. 39, no. 6, pp. 701–709, 1996. View at Publisher · View at Google Scholar
  87. R. L. Prigeon, S. E. Kahn, and D. Porte Jr., “Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus,” The Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 3, pp. 819–823, 1998. View at Publisher · View at Google Scholar
  88. P. Ferrari and P. Weidmann, “Editorial review: insulin, insulin sensitivity and hypertension,” Journal of Hypertension, vol. 8, no. 6, pp. 491–500, 1990. View at Publisher · View at Google Scholar
  89. J. W. Grinsell, C. K. Lardinois, A. Swislocki et al., “Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat,” American Journal of Hypertension, vol. 13, no. 4, pp. 370–375, 2000. View at Publisher · View at Google Scholar
  90. B. H. Sung, J. L. Izzo Jr., P. Dandona, and M. F. Wilson, “Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus,” Hypertension, vol. 34, no. 1, pp. 83–88, 1999. View at Google Scholar
  91. A. Uchida, T. Nakata, T. Hatta et al., “Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR,” Life Sciences, vol. 61, no. 4, pp. 455–464, 1997. View at Publisher · View at Google Scholar
  92. A. B. Walker, P. D. Chattington, R. E. Buckingham, and G. Williams, “The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats,” Diabetes, vol. 48, no. 7, pp. 1448–1453, 1999. View at Publisher · View at Google Scholar
  93. K. Iijima, M. Yoshizumi, J. Ako et al., “Expression of peroxisome proliferator-activated receptor ? (PPAR?) in rat aortic smooth muscle cells,” Biochemical and Biophysical Research Communications, vol. 247, no. 2, pp. 353–356, 1998. View at Publisher · View at Google Scholar
  94. R. E. Law, S. Goetze, X.-P. Xi et al., “Expression and function of PPAR? in rat and human vascular smooth muscle cells,” Circulation, vol. 101, no. 11, pp. 1311–1318, 2000. View at Google Scholar
  95. N. Marx, U. Schönbeck, M. A. Lazar, P. Libby, and J. Plutzky, “Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells,” Circulation Research, vol. 83, no. 11, pp. 1097–1103, 1998. View at Google Scholar
  96. F. Zhang, J. R. Sowers, J. L. Ram, P. R. Standley, and J. D. Peuler, “Effects of pioglitazone on calcium channels in vascular smooth muscle,” Hypertension, vol. 24, no. 2, pp. 170–175, 1994. View at Google Scholar
  97. H. Y. Zhang, S. R. Reddy, and T. A. Kotchen, “Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity,” Hypertension, vol. 24, no. 1, pp. 106–110, 1994. View at Google Scholar
  98. T. Fujiwara, T. Ohsawa, S. Takahashi et al., “Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats,” Life Sciences, vol. 63, no. 22, pp. 2039–2047, 1998. View at Publisher · View at Google Scholar
  99. A. Sugawara, K. Takeuchi, A. Uruno et al., “Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-? in vascular smooth muscle cells,” Endocrinology, vol. 142, no. 7, pp. 3125–3134, 2001. View at Publisher · View at Google Scholar
  100. M. Haneda, S.-I. Araki, M. Togawa, T. Sugimoto, M. Isono, and R. Kikkawa, “Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions,” Diabetes, vol. 46, no. 5, pp. 847–853, 1997. View at Publisher · View at Google Scholar
  101. R. Kikkawa, M. Haneda, T. Uzu, D. Koya, T. Sugimoto, and Y. Shigeta, “Translocation of protein kinase C α and ζ in rat glomerular mesangial cells cultured under high glucose conditions,” Diabetologia, vol. 37, no. 8, pp. 838–841, 1994. View at Publisher · View at Google Scholar
  102. D. Koya, M. R. Jirousek, Y.-W. Lin, H. Ishii, K. Kuboki, and G. L. King, “Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats,” Journal of Clinical Investigation, vol. 100, no. 1, pp. 115–126, 1997. View at Publisher · View at Google Scholar
  103. D. Koya, I.-K. Lee, H. Ishii, H. Kanoh, and G. L. King, “Prevention of glomerular dysfunction in diabetic rats by treatment with d-α-tocopherol,” Journal of the American Society of Nephrology, vol. 8, no. 3, pp. 426–435, 1997. View at Google Scholar
  104. J. W. Baynes and S. R. Thorpe, “Role of oxidative stress in diabetic complications: a new perspective on an old paradigm,” Diabetes, vol. 48, no. 1, pp. 1–9, 1999. View at Publisher · View at Google Scholar
  105. P. Dandona, K. Thusu, S. Cook et al., “Oxidative damage to DNA in diabetes mellitus,” The Lancet, vol. 347, no. 8999, pp. 444–445, 1996. View at Publisher · View at Google Scholar
  106. J. Leinonen, T. Lehtimäki, S. Toyokuni et al., “New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus,” FEBS Letters, vol. 417, no. 1, pp. 150–152, 1997. View at Publisher · View at Google Scholar
  107. G. F. Davies, R. L. Khandelwal, L. Wu, B. H. Juurlink, and W. J. Roesler, “Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-γ (PPARγ)-independent, antioxidant-related mechanism,” Biochemical Pharmacology, vol. 62, no. 8, pp. 1071–1079, 2001. View at Publisher · View at Google Scholar
  108. T. Fukui, T. Noma, K. Mizushige, Y. Aki, S. Kimura, and Y. Abe, “Dietary troglitazone decreases oxidative stress in early stage type II diabetic rats,” Life Sciences, vol. 66, no. 21, pp. 2043–2049, 2000. View at Publisher · View at Google Scholar
  109. I. Inoue, S. Katayama, K. Takahashi et al., “Troglitazone has a scavenging effect on reactive oxygen species,” Biochemical and Biophysical Research Communications, vol. 235, no. 1, pp. 113–116, 1997. View at Publisher · View at Google Scholar
  110. A. Gumieniczek, “Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits,” Life Sciences, vol. 74, no. 5, pp. 553–562, 2003. View at Publisher · View at Google Scholar
  111. A. Gumieniczek, “Effects of pioglitazone on hyperglycemia-induced alterations in antioxidative system in tissues of alloxan-treated diabetic animals,” Experimental and Toxicologic Pathology, vol. 56, no. 4-5, pp. 321–326, 2005. View at Publisher · View at Google Scholar
  112. A. D. Dobrian, S. D. Schriver, A. A. Khraibi, and R. L. Prewitt, “Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity,” Hypertension, vol. 43, no. 1, pp. 48–56, 2004. View at Publisher · View at Google Scholar
  113. T. Furuta, T. Saito, T. Ootaka et al., “The role of macrophages in diabetic glomerulosclerosis,” American Journal of Kidney Diseases, vol. 21, no. 5, pp. 480–485, 1993. View at Google Scholar
  114. K.-I. Shikata and H. Makino, “Role of macrophages in the pathogenesis of diabetic nephropathy,” Contributions to Nephrology, vol. 134, pp. 46–54, 2001. View at Publisher · View at Google Scholar
  115. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar
  116. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar
  117. P. R. Colville-Nash and D. W. Gilroy, “COX-2 and the cyclopentenone prostaglandins—a new chapter in the book of inflammation?” Prostaglandins and Other Lipid Mediators, vol. 62, no. 1, pp. 33–43, 2000. View at Publisher · View at Google Scholar
  118. H. Inoue, T. Tanabe, and K. Umesono, “Feedback control of cyclooxygenase-2 expression through PPARγ,” Journal of Biological Chemistry, vol. 275, no. 36, pp. 28028–28032, 2000. View at Publisher · View at Google Scholar
  119. A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001. View at Publisher · View at Google Scholar
  120. T. V. Petrova, K. T. Akama, and L. J. Van Eldik, “Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Δ12,14-prostaglandin J2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 8, pp. 4668–4673, 1999. View at Publisher · View at Google Scholar
  121. S. Vaidya, E. P. Somers, S. D. Wright, P. A. Detmers, and V. S. Bansal, “15-deoxy-Δ12,1412,14-prostaglandin J2 inhibits the β2 integrin-dependent oxidative burst: involvement of a mechanism distinct from peroxisome proliferator-activated receptor γ ligation,” The Journal of Immunology, vol. 163, no. 11, pp. 6187–6192, 1999. View at Google Scholar
  122. A. Rossi, P. Kapahi, G. Natoli et al., “Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I?B kinase,” Nature, vol. 403, no. 6765, pp. 103–108, 2000. View at Publisher · View at Google Scholar
  123. H. Sawano, M. Haneda, T. Sugimoto, K. Inoki, D. Koya, and R. Kikkawa, “15-deoxy-Δ12,14-prostaglandin J2 inhibits IL-1β-induced cyclooxygenase-2 expression in mesangial cells,” Kidney International, vol. 61, no. 6, pp. 1957–1967, 2002. View at Publisher · View at Google Scholar
  124. S. S. Ghosh, T. W. Gehr, S. Ghosh et al., “PPAR? ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase,” Kidney International, vol. 64, no. 1, pp. 52–62, 2003. View at Publisher · View at Google Scholar
  125. E. D. Crook, “The role of hypertension, obesity, and diabetes in causing renal vascular disease,” American Journal of the Medical Sciences, vol. 317, no. 3, pp. 183–188, 1999. View at Google Scholar
  126. B. C. van Jaarsveld, P. Krijnen, H. Pieterman et al., “The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis,” The New England Journal of Medicine, vol. 342, no. 14, pp. 1007–1014, 2000. View at Publisher · View at Google Scholar
  127. T. Sawamura, N. Kume, T. Aoyama et al., “An endothelial receptor for oxidized low-density lipoprotein,” Nature, vol. 386, no. 6620, pp. 73–77, 1997. View at Publisher · View at Google Scholar
  128. G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors a and ? induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998. View at Publisher · View at Google Scholar
  129. R. E. Law, W. P. Meehan, X.-P. Xi et al., “Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia,” Journal of Clinical Investigation, vol. 98, no. 8, pp. 1897–1905, 1996. View at Publisher · View at Google Scholar
  130. K. Murakami, K. Tobe, T. Ide et al., “A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-a (PPAR-a) and PPAR-?: effect of PPAR-a activation on abnormal lipid metabolism in liver of Zucker fatty rats,” Diabetes, vol. 47, no. 12, pp. 1841–1847, 1998. View at Publisher · View at Google Scholar
  131. M. Arici, R. Chana, A. Lewington, J. Brown, and N. J. Brunskill, “Stimulation of proximal tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome proliferator activated receptor-γ,” Journal of the American Society of Nephrology, vol. 14, no. 1, pp. 17–27, 2003. View at Publisher · View at Google Scholar
  132. S. Zafiriou, S. R. Stanners, T. S. Polhill, P. Poronnik, and C. A. Pollock, “Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses,” Kidney International, vol. 65, no. 5, pp. 1647–1653, 2004. View at Publisher · View at Google Scholar
  133. W. A. Wilmer, C. L. Dixon, C. Hebert, L. Lu, and B. H. Rovin, “PPAR-α ligands inhibit H2O2-mediated activation of transforming growth factor-β1 in human mesangial cells,” Antioxidants & Redox Signaling, vol. 4, no. 6, pp. 877–884, 2002. View at Google Scholar
  134. C.-M. Hao, R. Redha, J. Morrow, and M. D. Breyer, “Peroxisome proliferator-activated receptor δ activation promotes cell survival following hypertonic stress,” Journal of Biological Chemistry, vol. 277, no. 24, pp. 21341–21345, 2002. View at Publisher · View at Google Scholar
  135. T. Jiang, Z. Wang, G. Proctor et al., “Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway,” Journal of Biological Chemistry, vol. 280, no. 37, pp. 32317–32325, 2005. View at Publisher · View at Google Scholar
  136. S. Kume, T. Uzu, S.-I. Araki et al., “Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet,” Journal of the American Society of Nephrology, vol. 18, no. 10, pp. 2715–2723, 2007. View at Publisher · View at Google Scholar
  137. G. Proctor, T. Jiang, M. Iwahashi, Z. Wang, J. Li, and M. Levi, “Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes,” Diabetes, vol. 55, no. 9, pp. 2502–2509, 2006. View at Publisher · View at Google Scholar
  138. Y. Kamijo, K. Hora, K. Kono et al., “PPARa protects proximal tubular cells from acute fatty acid toxicity,” Journal of the American Society of Nephrology, vol. 18, no. 12, pp. 3089–3100, 2007. View at Publisher · View at Google Scholar